[ET Net News Agency, 30 April 2021] Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,
Ltd. (01349) said its net profit attributable to shareholders of the listed company was
RMB5.12 million for the first quarter of 2021, compared to the loss of RMB18.29 million of
the same period last year.
Revenue was RMB126.20 million, a year-on-year increase of 263.52%. (RC)